ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

NCT06498479 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

460

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: HS-20093
DRUG: Topotecan

Sponsor

Hansoh BioMedical R&D Company